down arrow

Cabaletta Bio, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US12674W1099
USD
2.56
0.22 (9.4%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2.452.63

52 Week

0.993.67
Valuation
Technical
Day's Volume

CASH

2.42 M

Shareholding (Mar 2025)

FII

14.65%

Held by 81 FIIs

DII

30.08%

Held by 49 DIIs

Promoter

13.21%

How big is Cabaletta Bio, Inc.?

22-Jun-2025

As of Jun 18, Cabaletta Bio, Inc. has a market capitalization of 167.74 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -126.76 million over the latest four quarters. The company reported shareholder's funds of 152.34 million and total assets of 188.98 million as of Dec 24.

Market Cap: As of Jun 18, Cabaletta Bio, Inc. has a market capitalization of 167.74 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Cabaletta Bio, Inc. reported net sales of 0.00 million and a net profit of -126.76 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 152.34 million and total assets of 188.98 million.

Read More

What does Cabaletta Bio, Inc. do?

22-Jun-2025

Cabaletta Bio, Inc. is a clinical stage biotechnology company focused on developing engineered T-cell therapies for B cell-mediated autoimmune diseases, with a market cap of approximately $167.74 million and a recent net profit of -$36 million.

Overview: <BR>Cabaletta Bio, Inc. is a clinical stage biotechnology company focused on the discovery and development of engineered T-cell therapies for B cell-mediated autoimmune diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -36 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 167.74 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.93 <BR>Return on Equity: -104.28% <BR>Price to Book: 1.38<BR><BR>Contact Details: <BR>Address: 2929 Arch St Ste 600, PHILADELPHIA PA: 19104-2857 <BR>Tel: 1 267 7593100 <BR>Fax: 1 302 6555049 <BR>Website: https://www.cabalettabio.com/

Read More

Who are in the management team of Cabaletta Bio, Inc.?

22-Jun-2025

As of March 2022, the management team of Cabaletta Bio, Inc. includes Dr. Steven Nichtberger as Chairman, President, CEO, and Co-Founder, along with independent directors Dr. Catherine Bollard, Dr. Brian Daniels, Mr. Richard Henriques, and Mr. Mark Simon.

As of March 2022, the management team of Cabaletta Bio, Inc. includes Dr. Steven Nichtberger, who serves as the Chairman of the Board, President, Chief Executive Officer, and Co-Founder. Additionally, the board features several independent directors: Dr. Catherine Bollard, Dr. Brian Daniels, Mr. Richard Henriques, and Mr. Mark Simon.

Read More

Is Cabaletta Bio, Inc. technically bullish or bearish?

20-Sep-2025

As of September 3, 2025, Cabaletta Bio, Inc. is in a mildly bearish trend, indicated by daily moving averages and KST signals, despite recent outperformance against the S&P 500, with a 1-year return of -51.34% compared to the S&P 500's 17.14%.

As of 3 September 2025, the technical trend for Cabaletta Bio, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish outlook and the KST showing a mildly bearish signal on both weekly and monthly time frames. However, the weekly MACD and Dow Theory are mildly bullish, providing some counterbalance. The stock has outperformed the S&P 500 over the past week and month, with returns of 20.44% and 23.16% respectively, but has significantly underperformed over the longer terms, particularly with a 1-year return of -51.34% compared to the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 154 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.98

stock-summary
Return on Equity

-80.84%

stock-summary
Price to Book

0.86

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-45 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
63.06%
0%
63.06%
6 Months
17.43%
0%
17.43%
1 Year
-28.09%
0%
-28.09%
2 Years
-84.02%
0%
-84.02%
3 Years
-48.18%
0%
-48.18%
4 Years
-77.08%
0%
-77.08%
5 Years
-82.88%
0%
-82.88%

Cabaletta Bio, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Cabaletta Bio, Inc. technically bullish or bearish?

As of 3 September 2025, the technical trend for Cabaletta Bio, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish outlook and the KST showing a mildly bearish signal on both weekly and monthly time frames. However, the weekly MACD and Dow Theory are mildly bullish, providing some counterbalance. The stock has outperformed the S&P 500 over the past week and month, with returns of 20.44% and 23.16% respectively, but has significantly underperformed over the longer terms, particularly with a 1-year return of -51.34% compared to the S&P 500's 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-228.87%
EBIT to Interest (avg)
-71.58
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.93
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.04
EV to EBIT
-0.10
EV to EBITDA
-0.10
EV to Capital Employed
1.48
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1505.51%
ROE (Latest)
-104.28%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 47 Schemes (41.94%)

Foreign Institutions

Held by 81 Foreign Institutions (14.65%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -63.41% vs -90.34% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-45.40",
          "val2": "-29.90",
          "chgp": "-51.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.60",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-45.10",
          "val2": "-27.60",
          "chgp": "-63.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -71.20% vs -27.74% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-120.30",
          "val2": "-73.20",
          "chgp": "-64.34%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.70",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-115.90",
          "val2": "-67.70",
          "chgp": "-71.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-45.40
-29.90
-51.84%
Interest
0.60
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-45.10
-27.60
-63.41%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -63.41% vs -90.34% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-120.30
-73.20
-64.34%
Interest
0.70
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-115.90
-67.70
-71.20%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -71.20% vs -27.74% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Cabaletta Bio, Inc. stock-summary
stock-summary
Cabaletta Bio, Inc.
Pharmaceuticals & Biotechnology
Cabaletta Bio Inc. is a clinical stage biotechnology company. The Company is focused on discovery and development of engineered T-cell therapies for B cell-mediated autoimmune diseases. The T cells are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. The Company’s lead CAAR T cell product candidate are designed based on chimeric antigen receptor, and its T cell technology has been developed and is marketed for the treatment of B cell cancers. The Company has discovered and developed four product candidates, including its lead product candidate, to potentially treat patients with mucosal pemphigus vulgaris (mPV), and three additional product candidates that have demonstrated specific and selective target engagement in vitro. Its product pipelines include DSG3-CAART, DSG3/1-CAART, Musk-CAART and FVIII-CAART.
Company Coordinates stock-summary
Company Details
2929 Arch St Ste 600 , PHILADELPHIA PA : 19104-2857
stock-summary
Tel: 1 267 7593100
stock-summary
https://www.cabalettabio.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."